SEP
IBB icon

Signature Equity Partners’s iShares Biotechnology ETF IBB Stock Holding History

Signature Equity Partners’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.33K Buy
+7
New +$1.2K ﹤0.01% 1258
2026
Q1 		– Sell
-20
Closed -$3.38K – 1601
2025
Q4 		$3.38K Buy
+20
New +$3.25K ﹤0.01% 1092

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.9% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $22.8B AUM 28.56% 1-Year Est. Return

Signature Equity Partners's IBB Position: Q2 2026 in Review

Signature Equity Partners opened a new position in iShares Biotechnology ETF (IBB) in Q2 2026: 7 shares worth $1.33K. The stake represents ﹤0.01% of the portfolio and ranks #1258 among its holdings. This is a return to the name: Signature Equity Partners previously reported a position in IBB as recently as Q4 2025.

Signature Equity Partners first reported a position in IBB in Q4 2025 and has held it in 2 quarters since. The position peaked at $3.38K in Q4 2025. 960 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

  • Signature Equity Partners held 7 shares of iShares Biotechnology ETF worth $1.33K as of Q2 2026.
  • iShares Biotechnology ETF was a new Signature Equity Partners position in Q2 2026.
  • iShares Biotechnology ETF made up ﹤0.01% of Signature Equity Partners's portfolio in Q2 2026, its #1258 holding.
  • Signature Equity Partners first reported a position in iShares Biotechnology ETF in Q4 2025 and has held it in 2 quarters since.
  • Signature Equity Partners's iShares Biotechnology ETF position peaked at $3.38K in Q4 2025.
  • 960 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on Signature Equity Partners's 13F filing for Q2 2026, filed 30 Jul 2026.